» Articles » PMID: 27023284

Bone Health and HIV in Resource-limited Settings: a Scoping Review

Overview
Date 2016 Mar 30
PMID 27023284
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Sub-Saharan Africa and other resource-limited settings (RLS) bear the greatest burden of the HIV epidemic globally. Advantageously, the expanding access to antiretroviral therapy (ART) has resulted in increased survival of HIV individuals in the last 2 decades. Data from resource rich settings provide evidence of increased risk of comorbid conditions such as osteoporosis and fragility fractures among HIV-infected populations. We provide the first review of published and presented data synthesizing the current state of knowledge on bone health and HIV in RLS.

Recent Findings: With few exceptions, we found a high prevalence of low bone mineral density (BMD) and hypovitaminosis D among HIV-infected populations in both RLS and resource rich settings. Although most recognized risk factors for bone loss are similar across settings, in certain RLS there is a high prevalence of both non-HIV-specific risk factors and HIV-specific risk factors, including advanced HIV disease and widespread use of ART, including tenofovir disoproxil fumarate, a non-BMD sparing ART. Of great concern, we neither found published data on the effect of tenofovir disoproxil fumarate initiation on BMD, nor any data on incidence and prevalence of fractures among HIV-infected populations in RLS.

Summary: To date, the prevalence and squeal of metabolic bone diseases in RLS are poorly described. This review highlights important gaps in our knowledge about HIV-associated bone health comorbidities in RLS. This creates an urgent need for targeted research that can inform HIV care and management guidelines in RLS.

Citing Articles

Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in....

Matovu F, Kiwanuka N, Nabwana M, Scholes D, Musoke P, Fowler M Lancet Glob Health. 2022; 10(5):e694-e704.

PMID: 35427526 PMC: 9449816. DOI: 10.1016/S2214-109X(22)00080-8.


Bone Mineral Density in Antiretroviral Therapy-Naïve HIV-1-Infected Young Adult -Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda.

Matovu F, Nabwana M, Kiwanuka N, Scholes D, Isingel E, Nolan M JBMR Plus. 2021; 5(2):e10446.

PMID: 33615111 PMC: 7872338. DOI: 10.1002/jbm4.10446.


Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.

Stranix-Chibanda L, Tierney C, Sebikari D, Aizire J, Dadabhai S, Zanga A PLoS One. 2021; 16(2):e0246272.

PMID: 33544759 PMC: 7864465. DOI: 10.1371/journal.pone.0246272.


Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda.

Mwaka E, Munabi I, Castelnuovo B, Kaimal A, Kasozi W, Kambugu A PLoS One. 2021; 16(2):e0246389.

PMID: 33544754 PMC: 7864439. DOI: 10.1371/journal.pone.0246389.


Falls in people living with HIV: a scoping review.

Charumbira M, Berner K, Louw Q BMJ Open. 2020; 10(11):e034872.

PMID: 33148721 PMC: 7674634. DOI: 10.1136/bmjopen-2019-034872.


References
1.
Pinto Neto L, Ragi-Eis S, Vieira N, Soprani M, Neves M, Ribeiro-Rodrigues R . Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. J Clin Densitom. 2011; 14(4):434-9. DOI: 10.1016/j.jocd.2011.06.004. View

2.
Rey D, Treger M, Sibilia J, Priester M, Bernard-Henry C, Cheneau C . Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART. Infect Dis (Lond). 2014; 47(2):88-95. DOI: 10.3109/00365548.2014.968610. View

3.
Mondy K, Tebas P . Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36(Suppl 2):S101-5. DOI: 10.1086/367566. View

4.
Berenson A, Breitkopf C, Grady J, Rickert V, Thomas A . Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004; 103(5 Pt 1):899-906. DOI: 10.1097/01.AOG.0000117082.49490.d5. View

5.
Navarro M, Sosa M, Saavedra P, Lainez P, Marrero M, Torres M . Poverty is a risk factor for osteoporotic fractures. Osteoporos Int. 2008; 20(3):393-8. DOI: 10.1007/s00198-008-0697-9. View